Guías Clínicas
105
Guías tam izaje, d iagn óstico y tratam ien to de l hepa toca rcinoma - Sociedad Chilena de Gastroenterología
Chemoinfusion for Hepatocellular
Carcinoma as Downstaging Therapy and
a Bridge toward Liver Transplantation.
Am J Transpl. 2009;9:1158-68.
233.- Cillo U, Vitale A, Grigoletto F, Gringeri
E. Intention-to-Treat Analysis of
Liver Transplantation in Selected,
Aggressively Treated CHC Patients
Exceeding the Milan Criteria. Am J
Transpl. 2007;7:972-81.
234.- Graziadei I, Sandmueller H,
Waldenberger P, Koenigsrainer
A, Nachbaur K, Jaschke W, et al.
Chemoembolization Followed by Liver
Transplantation for Hepatocellular
Carcinoma Impedes Tumor Progression
While on the Waiting List and Leads to
Excellent Outcome. Liver Transplant.
2003;9:557-63.
235.- Liver CHC Criteria for auto approval
Internet. Available from: https://
optn.transplant.hrsa.gov/media/1922/
liver_CHC_criteria_for_auto_
approval_20160815.pdf
236.- Agopian VG, Morshedi MM,
McWilliams J, Harlander-Locke
MP, Markovic D, Zarrinpar A, et al.
Complete Pathologic Response
to Pretransplant Locoregional
Therapy for Hepatocellular Carcinoma
Defines Cancer Cure After Liver
Transplantation: Analysis of 501
Consecutively Treated Patients. Ann
Surg. 2015;262:536-45.
237.- Otto G, Herber S, Heise M, Lohse AW,
Mo C, Bittinger F, et al. Response to
Transarterial Chemoembolization as
a Biological Selection Criterion for
Liver Transplantation in Hepatocellular
Carcinoma. Liver Transplant.
2006;12(8):1260-7.
238.- Yao FY, Breitenstein S, Broelsch CE,
Dufour J, Sherman M. Does a Patient
Qualify for Liver Transplantation After
the Down-Staging of Hepatocellular
Carcinoma? Liver Transplant.
2011;17:S109-16.
239.- Hołówko W, Wróblewski T, Wojtaszek
M, Grąt M, Kobryń K, Ziarkiewicz-
Wróblewska B, et al. Transarterial
Chemoembolization Prior to Liver
Transplantation in Patients with
Hepatocellular Carcinoma. Ann
Transplant. 2015;20:764-8.
240.- Kim P, Onaca N, Chinnakotla S, Davis
G, Jennings L, Mckenna G, et al.
Tumor Biology and Pre-Transplant
Locoregional Treatments Determine
Outcomes in Patients with T3
Hepatocellular Carcinoma Undergoing
Liver Transplantation. Clin Transpl.
2013;27:311-8.
241.- Sebayel MI Al, Elsiesy H, Al-hamoudi
W, Alabbad S, Elsheikh Y, Elbeshbeshy
H, et al. Effect of Downstaging and
Bridging of Hepatocellular Carcinoma
on Survival Following Liver Transplant:
A Single Center Experience. Exp Clin
Transpl. 2017;15:7-11.
242.- Emami B, Lyman J, Brown A, Coia
L, Goiten M, Munzenrider JE, et
al. Tolerance of Normal Tissue to
Therapeutic Irradiation. Inr J Radiat
Oncol tliol Phys. 1991;21:109-22.
243.- Muñoz-Schuffenegger P, Ng S, Dawson
L. Radiation-Induced Liver Toxicity.
Semin Radiat Oncol. 2017;27:350-7.
244.- Murray LJ, Dawson LA. Advances in
Stereotactic Body Radiation Therapy for
Hepatocellular Carcinoma. Semin Radiat
Oncol. 2017;27:247-55.
245.- Huo YR, Eslick GD. Transcatheter
Arterial Chemoembolization Plus
Radiotherapy Compared With
Chemoembolization Alone for
Hepatocellular Carcinoma: A Systematic
Review and Meta-analysis. JAMA
Oncol. 2015;1:756-65.
246.- Abdel-Rahman O, Elsayed Z. External
Beam Radiotherapy for Unresectable
Hepatocellular Carcinoma (Review).
Cochrane Database Syst Rev.
2017;(3):CD011314.
247.- Bujold A, Massey CA, Kim JJ, Brierley
J, Cho C, Wong RKS, et al. Sequential
Phase I and II Trials of Stereotactic Body
Radiotherapy for Locally Advanced
Hepatocellular Carcinoma. J Clin Oncol.
2013;31:1631-9.
248.- Andolino DL, Johnson CS, Maluccio
M, Kwo P, Tector AJ, Zook J, et al.
Stereotactic Body Radiotherapy for
Primary Hepatocellular Carcinoma. Int J
Radiat Oncol Biol Phys. 2011;81:e447-
53.
249.- Yoon SM, Ryoo B-Y, Lee SJ,
Kim JH, Shin JH, An JH, et al.
Efficacy and Safety of Transarterial
Chemoembolization Plus External
Beam Radiotherapy vs Sorafenib
in Hepatocellular Carcinoma With
Macroscopic Vascular Invasion: A
Randomized Clinical Trial. JAMA
Oncol. 2018;4:661-9.
250.- Sapir E, Tao Y, Schipper MJ, Bazzi
L, Novelli PM, Devlin P, et al.
Stereotactic Body Radiation Therapy
as an Alternative to Transarterial
Chemoembolization for Hepatocellular
Carcinoma. Int J Radiat Oncol Biol
Phys. 2018;100:122-30.
251.- Dionisi F, Widesott L, Lorentini S,
Amichetti M. Is There a Role for
Proton Therapy in the Treatment of
Hepatocellular Carcinoma? A Systematic
Review. Radiother Oncol. 2014;111:1-
10.
252.- Llovet JM, Ricci S, Mazzaferro V,
Hilgard P, Gane E, Blanc J, et al.
Sorafenib in Advanced Hepatocellular
Carcinoma. N Engl J Med.
2008;359:378-90.
253.- Cheng A, Kang Y, Chen Z, Tsao C, Qin
S, Kim JS, et al. Efficacy and Safety of
Sorafenib in Patients in the Asia-Pacific
Region with Advanced Hepatocellular
Carcinoma: A Phase III Randomised,
Double-blind, Placebo-controlled Trial.
Lancet Oncol. 2009;10:25-34.
254.- Bruix J, Raoul J, Sherman M,
Mazzaferro V, Bolondi L, Craxi A, et
al. Efficacy and Safety of Sorafenib in
Patients with Advanced Hepatocellular
Carcinoma: Subanalyses of a Phase III
Trial. J Hepatol. 2012;57:821-9.
255.- D’amico G, García-Tsao G, Pagliaro
L. Natural History and Prognostic
Indicators of Survival in Cirrhosis: A
Systematic Review of 118 studies. J
Hepatol. 2006;44:217-31.
256.- Kudo M, Finn RS, Qin S, Han K,
Ikeda K, Piscaglia F, et al. Lenvatinib
Versus Sorafenib in First-line Treatment
of Patients with Unresectable
Hepatocellular Carcinoma: A
Randomised Phase 3 Non-inferiority
Trial. Lancet. 2018;391:1163-73.
257.- Bruix J, Qin S, Merle P, Granito A,
Huang Y, Bodoky G, et al. Regorafenib
for Patients with Hepatocellular
Carcinoma Who Progressed on Sorafenib
Treatment (RESORCE): A Randomised,
Double-blind, placebo-controlled, phase
3 trial. Lancet. 2017;389:56-66.
258.- Abou-Alfa GK, Meyer T, Cheng A-L,
El-Khoueiry AB, Rimassa L, Ryoo
B-Y, et al. Cabozantinib in Patients
with Advanced and Progressing
Gastroenterol. latinoam 2019; Vol 30, Nº 2: 64-106